Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.

Cancer medicine - 1 Dec 2023

Chen Enbo, Jiao Changqing, Yu Jian, Gong Yu, Jin Duo, Ma Xiaoyu, Cui Jianling, Wu Zhonghui, Zhou Junjie, Wang Haixia, Su Bobing, Ge Jian

Abstract excerpt

BACKGROUND: The European LeukemiaNet (ELN) risk classification system for acute myeloid leukemia (AML) patients has been used worldwide. In 2022, the ELN risk classification system modified risk genes including CEBPA mutation status, myelodysplasia-related (MR) gene mutations and internal tandem duplications of FLT3 (FLT3-ITD). METHODS: We include newly diagnosed de novo AML patients at our center from January...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leukemia, Myeloid, Acute
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Nucleophosmin

Share to Prognosis

Share to Risk Assessment

Share to Risk Factors

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 38098254
DOI: 10.1002/cam4.6696
PMCID: PMC10757130

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of 2022 European LeukemiaNet risk classification system in real-world cohort from China.PMID 38098254Read ↗

Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.Semantic proximity Read ↗

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.Semantic proximity Read ↗

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.Semantic proximity Read ↗

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.Semantic proximity Read ↗

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.Semantic proximity Read ↗

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Semantic proximity Read ↗

Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML.Semantic proximity Read ↗

A practical algorithm for acute myeloid leukaemia diagnosis following the updated 2022 classifications.Semantic proximity Read ↗

Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Real-world genomic profiling of acute myeloid leukemia and the impact of European LeukemiaNet risk stratification 2022 update.Semantic proximity Read ↗

How I treat AML incorporating the updated classifications and guidelines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.